Equity
€150,137 ▲ 1.1%
PharmaSpace has made a profit without a break since 2022.
PharmaSpace
Lifetime
9 annual accounts with figures on one time axispeak €341,697 (2025)
€321,507▼ 5.9%
lowest -€25,565 (2021)
€46,633▼ 10.8%
peak €150,137 (2026)
€150,137▲ 1.1%
€344,922▲ 2.0%
peak 2.8 FTE (2024)
2.4 FTE▼ 4.0%
Board4 names since 2017
3 directors and 2 others
Owners
Documentsfilings and deeds
29-10-202694 days before the deadline
2026abbreviated format
Cash from €39,536 to €52,089
Key points
from the 2026 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 26,973 companies had the same profile as PharmaSpace has now. Each dot stands for 68 companies, two years later.
94.8%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 26,973 companies, not a prediction for PharmaSpace. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 02-06-2017
Manager, since 02-06-2017
Director, , since 02-06-2017
- 99.5%equity €705,767 (2025) · 2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0676525015
Registered office moved within Ghent
New registered office: Kortrijksesteenweg 1133, 9051 Gent (Sint-Denijs-Westrem) · Previous registered office: Hogeheerweg 63, 9051 Gent (Sint-Denijs-Westrem) · Changes of role: (director) and (director) · General meeting of 26-12-2023 · Gazette deed
Resignation: (manager)
General meeting of 30-09-2019 · Gazette deed
First establishment
Kortrijksesteenweg 1133, Ghent
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PharmaSpace Ghent | €495,059 | €321,507 | 30.3% | 2.4 |
| APOTHEEK RABOT Ghent | €467,914 | €283,258 | 7.1% | 2.4 |
| Apotheek Klein-Sinaai Stekene | €544,832 | €347,493 | 36.6% | 2 |
| PHARMACIE VANDERVELLEN Woluwe-Saint-Lambert | €439,239 | €305,680 | 4.8% | 2.6 |
| MEUDON PHARMA Woluwe-Saint-Lambert | €508,899 | €282,475 | 43.0% | 2.7 |
| APOTHEEK MEESSCHAERT Veurne | €574,635 | €342,069 | 52.2% | 2.5 |
| PHARMACIE VANDECASTEELE Woluwe-Saint-Lambert | €388,091 | €322,062 | 48.8% | 2.6 |
These companies have the same main activity as PharmaSpace: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €388,000 and €575,000, founded between 2014 and 2016.
Official details
Source: KBO- Status
- Active since 02-06-2017Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 3 others
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 30-06-2026
- Establishment unit
- 2.264.862.4039051 Ghent, since 01-07-2017
- Financial year end
- 30 June
- Peppol
- Reachable since 27-03-2026
Annual accounts to 30-06-2026
- €495,059▲ 1.7%
- Employeeson 30-06-2026
- 3=
- Filing
- Filed on 29-10-2026, 94 days before the end of the filing period
Insights on PharmaSpace
PharmaSpace files the abbreviated format. That format states no turnover. The gross margin rose from €128,389 in 2018 to €321,507 in 2026.
holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PharmaSpace
- What is the company number of PharmaSpace?
- The company number of PharmaSpace is 0676.525.015. The VAT number is the same number with BE in front: BE 0676.525.015.
- Where is PharmaSpace based?
- The registered office is at Hogeheerweg 63, 9051 Ghent.Company details
- What does PharmaSpace do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PharmaSpace?
- PharmaSpace is a private limited company (BV).
- When was PharmaSpace founded?
- PharmaSpace was founded on 02-06-2017.
- Is PharmaSpace still active?
- Yes, PharmaSpace is an active enterprise in the KBO register.
- How many employees does PharmaSpace have?
- PharmaSpace had an average of 2.4 full-time equivalents in financial year 2026, according to the filed annual accounts.Financials
- Which joint committee does PharmaSpace fall under?
- In its 30-06-2026 annual accounts, PharmaSpace states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of PharmaSpace?
- The turnover in financial year 2026 is ≈ €1.2m. This figure is estimated from the gross margin of €321,507 and 47 comparable companies (NACE 477). It probably lies between €870,000 and €1.8m.
- Is PharmaSpace profitable?
- In financial year 2026, PharmaSpace made a profit of €46,633.
- Where can I find the annual accounts of PharmaSpace?
- PharmaSpace filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
- When are the next annual accounts of PharmaSpace due?
- PharmaSpace must file the annual accounts for financial year 2027 by 31-01-2028.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.